Letter/Communication
Letter by Robinson regarding articles, "bringing back targets to 'IMPROVE' atherosclerotic cardiovascular disease outcomes: The duel for dual goals; Are two targets better than one?" and "achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT"
Circulation (New York, N.Y.), Vol.133(13), pp.e461-e461
2016
DOI: 10.1161/CIRCULATIONAHA.115.019345
PMID: 27022048
Abstract
Bolula et al1 report the rates of major cardiovascular events for groups of patients achieving low-density lipoprotein cholesterol (LDL-C) <70 mg/dL or ≥70 mg/dL and high-sensitivity C-reactive protein (hs-CRP) <2 mg/L or ≥2 mg/L after 1 month of follow-up for participants in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). The results not surprisingly are consistent with the reports of others, in that patients with both LDL-C <70 mg/dL and hs-CRP <2 mg/L on treatment are at lower …
Details
- Title: Subtitle
- Letter by Robinson regarding articles, "bringing back targets to 'IMPROVE' atherosclerotic cardiovascular disease outcomes: The duel for dual goals; Are two targets better than one?" and "achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT"
- Creators
- Jennifer G Robinson
- Resource Type
- Letter/Communication
- Publication Details
- Circulation (New York, N.Y.), Vol.133(13), pp.e461-e461
- DOI
- 10.1161/CIRCULATIONAHA.115.019345
- PMID
- 27022048
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Language
- English
- Date published
- 2016
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995132002771
Metrics
15 Record Views